TROP2 drugs for Breast Cancer
3 tracked TROP2 drugs in the Breast Cancer race. The class explanation lives on the TROP2 page; the full indication pipeline across every mechanism is on the Breast Cancer page.
2 approved / phase 41 Phase 3
Head-to-head evidence: Datopotamab Deruxtecan vs Sacituzumab Govitecan · Datopotamab Deruxtecan vs Sacituzumab Tirumotecan · Sacituzumab Govitecan vs Sacituzumab Tirumotecan